REFERENCES
- Mizutani A, Murakami K, Okajima K, Kira S, Mizutani S, Kudo K, Takatani J, Goto K, Hattori S, Noguchi T. Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock. 2005;24(3):281–287.
- Karabulut R, Sönmez K, Sancak B, Türkyilmaz Z, Demiroğullari B, Ozen IO, Ekingen G, Candan S, Başaklar AC, Kale N. Effects of amrinone on bilateral renal ischemia/reperfusion injury. Urol Res. 2002;30(3):164–168.
- Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001;59(6):2114–2125.
- Zheng X, Xie L, Qin J, Shen H, Chen Z, Jin Y. Effects of wortmannin on phosphorylation of PDK1, GSK3-beta, PTEN and expression of Skp2 mRNA after ischemia/reperfusion injury in the mouse kidney. Int Urol Nephrol. 2008;40(1):185–192.
- Anas C, Ozaki T, Maruyama S, Yamamoto T, Zu Gotoh M, Ono Y, Matsuo S. Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure. Int J Urol. 2007;14(3):219–225.
- Williams P, Lopez H, Britt D, Chan C, Ezrin A, Hottendorf R. Characterization of renal ischemia-reperfusion injury in rats. J Pharmacol Toxicol Methods. 1997;37(1):1–7.
- Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488–520.
- Jackson EK, Mi Z, Carcillo JA, Gillespie DG, Dubey RK. Phosphodiesterases in the rat renal vasculature. J Cardiovasc Pharmacol. 1997;30(6):798–801.
- Vernon MW, Heel RC, Brogden RN. Enoximone. A review of its pharmacological properties and therapeutic potential. Drugs. 1991;42(6):997–1017.
- Setoyama K, Ota H, Miura N, Fujiki M, Misumi K, Sakamoto H. Effects of milrinone on hemodynamics and regional blood flow in the hypoxic dog. J Vet Med Sci. 2002;64(6):499–503.
- Tobata D, Takao K, Mochizuki M, Nishimura R, Sasaki N. Effects of dopamine, dobutamine, amrinone and milrinone on regional blood flow in isoflurane anesthetized dogs. J Vet Med Sci. 2004;66(9):1097–1105.
- Lehtonen LA, Antila S, Pentikäinen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187–203.
- Leier CV, Meiler SE, Matthews S, Unverferth DV. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure. Am J Cardiol. 1987;60(5):27C–30C.
- Clifton G, McMahon G, Ryan J, Vargas R, Bekele T, Wallin D. The effects of enoximone on renal function in patients with congestive heart failure. Clin Pharmacol Ther. 1989;45(1):85–91.
- Berti S, Palmieri C, Ravani M, Bonini R, Iascone MR, Clerico A, Manfredi C, Iervasi G, Ferrazzi P, Biagini A. Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure. Cardiovasc Drugs Ther. 1996;10(1):81–87.
- Boldt J, Brosch C, Lehmann A, Suttner S, Isgro F. The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients. Anesth Analg. 2004;99(4):1009–1017.
- Loick HM, Möllhoff T, Berendes E, Hammel D, Van Aken H. Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass. Intensive Care Med. 1997;23(3):267–275.
- Santarpino G, Caroleo S, Onorati F, Dimastromatteo G, Abdalla K, Amantea B, Santangelo E, Gulletta E, Renzulli A. Inflammatory response to cardiopulmonary bypass with enoximone or steroids in patients undergoing myocardial revascularization: A preliminary report study. Int J Clin Pharmacol Ther. 2009;47(2):78–88.
- Chevion M. A site-specific mechanism for free radical induced biological damage: The essential role of redox-active transition metals. Free Radic Biol Med. 1988;5(1):27–37.